An iatrogenic orphan?

Abstract

In this issue of Blood, Wang and colleagues from the Mayo Clinic and the University of Iowa, describe the outcomes of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) and treated in the era of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) who are also found to have an underlying indolent lymphoma in the lymph nodes or the bone marrow.